Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Einstein (Sao Paulo) ; 18: eRC5876, 2020.
Artigo em Inglês, Português | MEDLINE | ID: mdl-33111813

RESUMO

A male patient with flu-like symptoms and tomography and laboratory diagnosis of severe acute respiratory syndrome. He developed acute cardiac dysfunction during admission and was submitted to a cardiac magnetic resonance imaging examination, which confirmed acute myocarditis, indicating cardiac involvement by coronavirus disease 2019. A review and discussion about coronavirus disease 2019-related cardiac manifestations are reported, focusing on the imaging findings to make diagnosis.


Assuntos
Infecções por Coronavirus/complicações , Miocardite/virologia , Pneumonia Viral/complicações , Betacoronavirus , Infecções por Coronavirus/diagnóstico , Humanos , Imagem por Ressonância Magnética , Masculino , Miocardite/diagnóstico por imagem , Pandemias , Pneumonia Viral/diagnóstico
3.
Arq. bras. cardiol ; 115(4): 720-775, out. 2020. tab, graf
Artigo em Português | LILACS, Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP | ID: biblio-1131346
4.
Einstein (Säo Paulo) ; 18: eRC5876, 2020. graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1133729

RESUMO

ABSTRACT A male patient with flu-like symptoms and tomography and laboratory diagnosis of severe acute respiratory syndrome. He developed acute cardiac dysfunction during admission and was submitted to a cardiac magnetic resonance imaging examination, which confirmed acute myocarditis, indicating cardiac involvement by coronavirus disease 2019. A review and discussion about coronavirus disease 2019-related cardiac manifestations are reported, focusing on the imaging findings to make diagnosis.


RESUMO Paciente do sexo masculino apresentando síndrome gripal aguda com diagnóstico tomográfico e laboratorial de infecção por síndrome respiratória aguda grave. Evoluiu com disfunção cardíaca aguda durante a internação, motivo pelo qual foi submetido à ressonância magnética cardíaca, que confirmou miocardite aguda, indicando acometimento cardíaco por COVID-19. Foram realizadas revisão e discussão sobre o acometimento cardíaco na COVID-19, com ênfase nos aspectos por imagem para o diagnóstico.

5.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 29(2 (Supl)): 201-201, abr.-jun. 2019. ilus
Artigo em Português | LILACS | ID: biblio-1009930

RESUMO

A prótese de Star-Edwards foi a primeira válvula mecânica a ser implantada no mundo, no ano de 1960. Cerca de 200.000 pacientes foram beneficiados com esse modelo, porém, caiu em desuso por suas frequentes complicações como hemólise, anemia e tromboembolismos, apesar de sua notável durabilidade. Neste artigo apresentamos um caso de paciente com a maior durabilidade com manutenção da funcionalidade da prótese S-E, já relatado na literatura. O paciente fez o seguimento cardiológico corretamente, bem como usou a anticoagulação adequada. Apresentou disfunção de outras valvas, porém a prótese S-E manteve-se estável e funcional. Inclusive, necessitou de cirurgia para troca valvar mitral, mas não da prótese de S-E em posição aórtica. Este relato foi realizado através da história clínica do paciente e do levantamento de dados da literatura sobre próteses valvares e sua durabilidade. Existem relatos de durabilidade de próteses valvares com aproximadamente 30 a 40 anos, mas nenhum relato próximo ou igual a este com 49 anos de durabilidade. A importância dos cuidados pós-operatórios, uso correto dos anticoagulantes e o seguimento clínico para controle das possíveis complicações da prótese, foi mostrada neste artigo através do relato desse caso


In 1960, the Starr-Edwards prosthesis became the first mechanical valve to be implanted, worldwide. Roughly 200,000 patients benefited from this model. However, it has now fallen out of use due to its frequent complications, such as hemolysis, anemia and thromboembolisms, despite its noteworthy durability. In this article, we present a case of a patient with the longest durability with maintenance of functionality of the S-E prosthesis reported in the literature. The patient had correctly followed the cardiological follow-up, including adequate use of anti-coagulant medications. The patient presented dysfunction in other valves, but the S-E prosthesis remained stable and functional. The patient even required mitral valve replacement surgery, but not for the S-E prosthesis in the aortic position. This report was based on patient's clinical history and a survey of the literature data on valve prostheses and their durability. There are reports of prostheses remaining stable for approximately 30 to 40 years, but none that came close to this one, which had lasted for 49 years The importance of postoperative care, the correct use of anti-coagulant medicines, and clinical follow-up to minimize the possible complications of the prosthesis, were shown in this article through this case report


Assuntos
Humanos , Masculino , Idoso , Próteses Valvulares Cardíacas , Valvas Cardíacas , Valva Aórtica , Estenose da Valva Aórtica/cirurgia , Ecocardiografia/métodos , Doenças das Valvas Cardíacas , Anticoagulantes/uso terapêutico
9.
Rev Assoc Med Bras (1992) ; 62(1): 32-7, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27008490

RESUMO

INTRODUCTION: the EuroSCORE II and STS are the most used scores for surgical risk stratification and indication of transcatheter aortic valve implantation (TAVI). However, its role as a tool for mortality prediction in patients undergoing TAVI is still unclear. OBJECTIVE: to evaluate the performance of the EuroSCORE II and STS as predictors of in-hospital and 30-day mortality in patients undergoing TAVI. METHODS: we included 59 symptomatic patients with severe aortic stenosis that underwent TAVI between 2010 and 2014. The variables were analyzed using Student's t-test and Fisher's exact test and the discriminative power was evaluated using receiver operating characteristic curve (ROC) and area under the curve (AUC) with a 95% confidence interval. RESULTS: mean age was 81±7.3 years, 42.3% men. The mean EuroSCORE II was 7.6±7.3 % and STS was 20.7±10.3%. Transfemoral procedure was performed in 88.13%, transapical in 3.38% and transaortic in 8.47%. In-hospital mortality was 10.1% and 30-day mortality was 13.5%. Patients who died had EuroSCORE II and STS higher than the survivors (33.7±16.7vs. 18.6±7.3% p=0,0001 for STS and 13.9±16.1 vs. 4.8±3.8% p=0.0007 for EuroSCORE II). The STS showed an AUC of 0.81 and the EuroSCORE II of 0.77 and there were no differences in the discrimination ability using ROC curves (p=0.72). CONCLUSION: in this cohort, the STS and EuroSCORE II were predictors of in-hospital and 30-days mortality in patients with severe aortic stenosis undergoing TAVI.


Assuntos
Medição de Risco/métodos , Substituição da Valva Aórtica Transcateter/mortalidade , Idoso , Idoso de 80 Anos ou mais , Estenose da Valva Aórtica/mortalidade , Estenose da Valva Aórtica/cirurgia , Brasil , Feminino , Mortalidade Hospitalar , Humanos , Masculino , Reprodutibilidade dos Testes , Estudos Retrospectivos , Fatores de Risco , Sensibilidade e Especificidade , Substituição da Valva Aórtica Transcateter/efeitos adversos
10.
Rev. Assoc. Med. Bras. (1992) ; 62(1): 32-37, Jan.-Feb. 2016. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: lil-777440

RESUMO

SUMMARY Introduction: the EuroSCORE II and STS are the most used scores for surgical risk stratification and indication of transcatheter aortic valve implantation (TAVI). However, its role as a tool for mortality prediction in patients undergoing TAVI is still unclear. Objective: to evaluate the performance of the EuroSCORE II and STS as predictors of in-hospital and 30-day mortality in patients undergoing TAVI. Methods: we included 59 symptomatic patients with severe aortic stenosis that underwent TAVI between 2010 and 2014. The variables were analyzed using Student's t-test and Fisher's exact test and the discriminative power was evaluated using receiver operating characteristic curve (ROC) and area under the curve (AUC) with a 95% confidence interval. Results: mean age was 81±7.3 years, 42.3% men. The mean EuroSCORE II was 7.6±7.3 % and STS was 20.7±10.3%. Transfemoral procedure was performed in 88.13%, transapical in 3.38% and transaortic in 8.47%. In-hospital mortality was 10.1% and 30-day mortality was 13.5%. Patients who died had EuroSCORE II and STS higher than the survivors (33.7±16.7vs. 18.6±7.3% p=0,0001 for STS and 13.9±16.1 vs. 4.8±3.8% p=0.0007 for EuroSCORE II). The STS showed an AUC of 0.81 and the EuroSCORE II of 0.77 and there were no differences in the discrimination ability using ROC curves (p=0.72). Conclusion: in this cohort, the STS and EuroSCORE II were predictors of in-hospital and 30-days mortality in patients with severe aortic stenosis undergoing TAVI.


RESUMO Introdução: STS e EuroSCORE II são os escores mais utilizados para a estratificação de risco cirúrgico e indicação do implante de válvula aórtica transcateter (TAVI). Entretanto, seu papel como ferramenta para predição de mortalidade em pacientes submetidos ao TAVI ainda é incerto. Objetivo: avaliar o desempenho do EuroSCORE II e STS como preditores de mortalidade intra-hospitalar em 30 dias em pacientes submetidos ao TAVI. Métodos: 59 pacientes com estenose aórtica importante submetidos ao TAVI entre 2010 e 2014. Variáveis foram analisadas por meio do teste t-Student e teste exato de Fisher, e o poder discriminativo foi avaliado pela curva ROC e área sob a curva, acompanhada de intervalo de confiança de 95%. Resultados: a idade média foi de 81±7,3 anos, 42,3% homens. Média do EuroSCORE II foi de 6,07±7,3%, e do STS, 20,7±10,3%. Procedimento transfemoral foi realizado em 88,13%, transapical, em 3,38% e transaórtico, em 8,47%. A mortalidade intra-hospitalar foi 10,1%, e em 30 dias, 13,5%. Os pacientes que evoluíram para óbito apresentavam STS e EuroSCORE II mais elevados que os sobreviventes (33,7±16,7% vs. 18,6±7,3%; p=0,0001 para STS e 13,9±16,1% vs. 4,8±3,8%; p=0,0007 para EuroSCORE II). O STS apresentou AUC de 0,81, e o EuroSCORE II, 0,77. Não houve diferença na capacidade de discriminação pelas curvas ROC (p=0,72). Conclusão: STS e EuroSCORE II foram preditores de mortalidade intra-hospitalar em 30 dias.

11.
Arq Bras Cardiol ; 105(4): 426-9, 2015 Oct.
Artigo em Inglês, Português | MEDLINE | ID: mdl-26559990

RESUMO

Prosthetic thrombosis is a rare complication, but it has high mortality and morbidity. Young women of childbearing age that have prosthetic heart valves are at increased risk of thrombosis during pregnancy due to changes in coagulation factors. Anticoagulation with adequate control and frequent follow-up if pregnancy occurs must be performed in order to prevent complications related to anticoagulant use. Surgery remains the treatment of choice for prosthetic heart valve thrombosis in most clinical conditions. Patients with metallic prosthetic valves have an estimated 5% risk of thrombosis during pregnancy and maternal mortality of 1.5% related to the event. Anticoagulation with vitamin K antagonists during pregnancy is related to varying degrees of complications at each stage of the pregnancy and postpartum periods. Warfarin sodium crosses the placental barrier and when used in the first trimester of pregnancy is a teratogenic agent, causing 1-3% of malformations characterized by fetal warfarin syndrome and also constitutes a major cause of miscarriage in 10-30% of cases. In the third trimester and at delivery, the use of warfarin is associated with maternal and neonatal bleeding in approximately 5 to 15% of cases, respectively. On the other hand, inadequate anticoagulation, including the suspension of the oral anticoagulants aiming at fetal protection, carries a maternal risk of about 25% of metallic prosthesis thrombosis, particularly in the mitral valve. This fact is also due to the state of maternal hypercoagulability with activation of coagulation factors V, VI, VII, IX, X, platelet activity and fibrinogen synthesis, and decrease in protein S levels. The Registry of Pregnancy and Cardiac Disease (ROPAC), assessing 212 pregnant women with metal prosthesis, showed that prosthesis thrombosis occurred in 10 (4.7%) patients and maternal hemorrhage in 23.1%, concluding that only 58% of patients with metallic prosthesis had a complication-free pregnancy.


Assuntos
Anticoagulantes/uso terapêutico , Fatores de Coagulação Sanguínea/efeitos dos fármacos , Próteses Valvulares Cardíacas/efeitos adversos , Período Pós-Parto/efeitos dos fármacos , Complicações Cardiovasculares na Gravidez/prevenção & controle , Trombose/prevenção & controle , Feminino , Idade Gestacional , Heparina/uso terapêutico , Humanos , Metais , Gravidez , Fatores de Risco , Varfarina/uso terapêutico
14.
Rev. bras. med. esporte ; 19(5): 339-342, set.-out. 2013. tab
Artigo em Português | LILACS-Express | LILACS | ID: lil-696049

RESUMO

INTRODUÇÃO: O exercício aeróbio é recomendado para o tratamento da hipertensão. Sua intensidade pode ser prescrita com base na porcentagem da frequência cardíaca máxima (%FCmáx) ou no consumo pico de oxigênio (%VO2pico) em que os limiares ventilatórios (LV) são alcançados. Entretanto, alguns hipertensos que iniciam o treinamento podem estar tomando betabloqueadores, o que pode influenciar esses parâmetros. OBJETIVO: verificar os efeitos do atenolol sobre os LV de hipertensos sedentários. MÉTODOS: Nove voluntários realizaram dois testes ergoespirométricos máximos após quatro semanas de tratamento com atenolol (25 mg administrado por via oral duas vezes por dia) e com placebo, administrados em ordem fixa e de forma cega. Durante os testes, a frequência cardíaca (FC), a pressão arterial (PA) e o VO2 no repouso, limiar anaeróbio (LA), ponto de compensação respiratória (PCR) e pico do esforço foram analisados. RESULTADOS: O VO2 aumentou progressivamente no exercício e seus valores foram semelhantes nos dois tratamentos. A PA sistólica e a FC também aumentaram no exercício, mas seus valores absolutos foram significativamente menores com o atenolol. Porém, o aumento da PA sistólica e da FC no exercício foi semelhante com os dois tratamentos. Assim, o percentual da FCmáx e o percentual do VO2pico em que LA e PCR foram alcançados não diferiram entre o placebo e o atenolol. CONCLUSÃO: O atenolol na dosagem de 50 mg/dia não afetou o percentual do VO2pico e da FCmáx em que os LV são atingidos, o que confirma que a prescrição de intensidade de treinamento com base nessas porcentagens pode ser mantida em hipertensos que recebem betabloqueadores.


INTRODUCTION: Aerobic exercise is recommended for the treatment of hypertension. Its intensity can be prescribed based on the percentage of maximum heart rate (% MHR) or peak oxygen consumption (VO2peak%) in which the ventilatory thresholds (VT) are achieved. However, some hypertensive patients who begin aerobic training may be receiving beta-blockers, which can influence these parameters. OBJECTIVE: To investigate the effects of atenolol on VT of sedentary hypertensive patients. METHODS: Nine volunteers performed two cardiopulmonary exercise tests until exhaustion after 4 weeks of treatment with atenolol (25 mg orally twice daily) and with placebo, administered in a fixed order and in a blinded manner. During the tests, heart rate (HR), blood pressure (BP), VO2 at rest, anaerobic threshold (AT), respiratory compensation point (RCP) and peak effort were analyzed. RESULTS: VO2 increased progressively throughout the exercise and the values were similar for both treatments. Systolic blood pressure and heart rate also increased progressively during the exercise, but their absolute values were significantly lower with atenolol. However, the increase in systolic BP and HR during exercise was similar in both treatments. Thus, the % of MHR and %VO2peak at which LA and PCR were achieved were not different between placebo and atenolol. CONCLUSION: Atenolol, at a dosage of 50mg/day, did not affect the % of VO2peak and % of MHR corresponding to the VTs, which confirms that prescription of training intensity based on these percentages is adequate to hypertensive patients receiving beta-blockers.

16.
In. Timerman, Sergio; Dallan, Luís Augusto Palma; Geovanini, Glaucylara reis. Síndromes coronárias agudas e emergências cardiovasculares / Acute coronary syndromes and cardiovascular emergencies. São Paulo, Atheneu, 2013. p.417-426.
Monografia em Português | LILACS | ID: lil-719905
17.
Arq Bras Cardiol ; 97(5 Suppl 1): 1-67, 2011.
Artigo em Português | MEDLINE | ID: mdl-22286365
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...